Updated Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in RRMM

Bhagirathbhai R. Dholaria, MBBS, assistant professor of medicine, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses updated findings from the phase 1 TRIMM-2 trial (NCT04108195) of talquetamab and daratumumab (Darzalex) for the treatment of relapsed/refractory multiple myeloma.

According to Dholaria, updated results from the trial were overall positive and showed the combination to be safe. Those treated with talquetamab at a weekly dose of 0.4 mg/kg had an overall response rate (ORR) of 71.4% vs 84.0% among patients who received the 0.8 mg/kg twice-weekly dose. In both of these cohorts, patients received 1800 mg of subcutaneous daratumumab.

Additionally, no new safety signals were found and most of the adverse effects were hematological. There was 1 treatment-related death on the trial as well.

Transcription:

0:08 | The major findings were that this combination appears to be safe, compared with what we have learned previously with talquetamab monotherapy data. There were no new serious safety signals found when daratumumab was added to talquetamab. The majority of the [adverse] effects were hematological. Around a quarter of the patients had grade 3 or 4 neutropenia, however, the risk of serious infection was modest. We had 1 treatment-related death in a patient who had infection, and the risk of cytokine release syndrome, as well as the neurotoxicity from the talquetamab, was relatively low. Although it happened in the majority of the patients, the severity was only greater 1 or 2 in the majority of the cases.

0:55 | And in terms of efficacy, in both cohorts, we saw overall response rates of greater than 70%, including quite encouraging overall response rates in a patient who had prior CAR [chimeric antigen receptor] T-cell therapy or exposure to other bispecific antibody therapies.